The NKG2D axis: an emerging target in cancer immunotherapy

Manufacturing development and clinical production of NKG2D chimeric antigen receptor–expressing T cells for autologous adoptive cell therapy

(2018) Joana M. Murad et al.   CYTOTHERAPY

Inhibition of Enhancer of zeste homolog 2 (EZH2) induces natural killer cell-mediated eradication of hepatocellular carcinoma cells

(2018) Suresh Bugide et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Antibody-mediated inhibition of MICA and MICB shedding promotes NK cell–driven tumor immunity

(2018) Lucas Ferrari de Andrade et al.   SCIENCE

The Role of Natural Killer Group 2, Member D in Chronic Inflammation and Autoimmunity

(2018) Marina Babic et al.   Frontiers in Immunology

More than Decoration: Roles for Natural Killer Group 2 Member D Ligand Expression by Immune Cells

(2018) Andrew P. Trembath et al.   Frontiers in Immunology

New Insights Into the Regulation of Natural-Killer Group 2 Member D (NKG2D) and NKG2D-Ligands: Endoplasmic Reticulum Stress and CEA-Related Cell Adhesion Molecule 1

(2018) Shuhei Hosomi et al.   Frontiers in Immunology

NK cell receptor NKG2D sets activation threshold for the NCR1 receptor early in NK cell development

(2018) Vedrana Jelenčić et al.   NATURE IMMUNOLOGY

NK cell-based immunotherapy for cancer

(2017) Fang Fang et al.   SEMINARS IN IMMUNOLOGY

The immunoreceptor NKG2D promotes tumour growth in a model of hepatocellular carcinoma

(2017) Sam Sheppard et al.   Nature Communications

Increasing TIMP3 expression by hypomethylating agents diminishes soluble MICA, MICB and ULBP2 shedding in acute myeloid leukemia, facilitating NK cell-mediated immune recognition

(2017) Aroa Baragaño Raneros et al.   Oncotarget

Natural Killer Cell Response to Chemotherapy-Stressed Cancer Cells: Role in Tumor Immunosurveillance

(2017) Alessandra Zingoni et al.   Frontiers in Immunology

Inhibition of bromodomain and extra-terminal (BET) proteins increases NKG2D ligand MICA expression and sensitivity to NK cell-mediated cytotoxicity in multiple myeloma cells: role of cMYC-IRF4-miR-125b interplay

(2016) Maria Pia Abruzzese et al.   Journal of Hematology & Oncology

IDH mutant gliomas escape natural killer cell immune surveillance by downregulation of NKG2D ligand expression

(2016) Xiaoran Zhang et al.   NEURO-ONCOLOGY

Selective targeting of IL-2 to NKG2D bearing cells for improved immunotherapy

(2016) Reza Ghasemi et al.   Nature Communications

Chimeric antigen receptor T-cell therapy for solid tumors

(2016) Kheng Newick et al.   Molecular Therapy-Oncolytics

Genetics, genomics, and evolutionary biology of NKG2D ligands

(2015) Raphael Carapito et al.   IMMUNOLOGICAL REVIEWS

T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial

(2015) Daniel W Lee et al.   LANCET

A shed NKG2D ligand that promotes natural killer cell activation and tumor rejection

(2015) W. Deng et al.   SCIENCE

Engineering CAR-T cells: Design concepts

(2015) Shivani Srivastava et al.   TRENDS IN IMMUNOLOGY

Axitinib induces DNA damage response leading to senescence, mitotic catastrophe, and increased NK cell recognition in human renal carcinoma cells

(2015) Maria Beatrice Morelli et al.   Oncotarget

The IMiDs targets IKZF-1/3 and IRF4 as novel negative regulators of NK cell-activating ligands expression in multiple myeloma

(2015) Cinzia Fionda et al.   Oncotarget

NKG2D Receptor and Its Ligands in Host Defense

(2015) L. L. Lanier   Cancer Immunology Research

Effect of NKG2D ligand expression on host immune responses

(2015) Marine Champsaur et al.   IMMUNOLOGICAL REVIEWS

MicroRNA-mediated down-regulation of NKG2D ligands contributes to glioma immune escape

(2015) Paula Codo et al.   Oncotarget

Methylation of NKG2D ligands contributes to immune system evasion in acute myeloid leukemia

(2014) A Baragaño Raneros et al.   GENES AND IMMUNITY

An Fc-optimized NKG2D-immunoglobulin G fusion protein for induction of natural killer cell reactivity against leukemia

(2014) Julia Steinbacher et al.   INTERNATIONAL JOURNAL OF CANCER

Two Novel NKG2D Ligands of the Mouse H60 Family with Differential Expression Patterns and Binding Affinities to NKG2D

(2014) A. Takada et al.   JOURNAL OF IMMUNOLOGY

Interaction of Monocytes with NK Cells upon Toll-Like Receptor-Induced Expression of the NKG2D Ligand MICA

(2014) M. Kloss et al.   JOURNAL OF IMMUNOLOGY

IL-2: The First Effective Immunotherapy for Human Cancer

(2014) S. A. Rosenberg   JOURNAL OF IMMUNOLOGY

Fc-Optimized NKG2D–Fc Constructs Induce NK Cell Antibody-Dependent Cellular Cytotoxicity against Breast Cancer Cells Independently of HER2/neu Expression Status

(2014) Stefanie Raab et al.   JOURNAL OF IMMUNOLOGY

Chimeric Antigen Receptor T Cells for Sustained Remissions in Leukemia

(2014) Shannon L. Maude et al.   NEW ENGLAND JOURNAL OF MEDICINE

Correction: Cellular Expression, Trafficking, and Function of Two Isoforms of Human ULBP5/RAET1G

(2014) Robert A. Eagle et al.   PLoS One

The DNA Damage Response: A Common Pathway in the Regulation of NKG2D and DNAM-1 Ligand Expression in Normal, Infected, and Cancer Cells

(2014) Cristina Cerboni et al.   Frontiers in Immunology

Regulation of Ligands for the NKG2D Activating Receptor

(2013) David H. Raulet et al.   Annual Review of Immunology

A GPI anchor explains the unique biological features of the common NKG2D-ligand allele MICA*008

(2013) Omodele Ashiru et al.   BIOCHEMICAL JOURNAL

A Chimeric Receptor with NKG2D Specificity Enhances Natural Killer Cell Activation and Killing of Tumor Cells

(2013) Y.-H. Chang et al.   CANCER RESEARCH

Chimeric NKG2D CAR-Expressing T Cell-Mediated Attack of Human Ovarian Cancer Is Enhanced by Histone Deacetylase Inhibition

(2013) De-Gang Song et al.   HUMAN GENE THERAPY

Shedding of endogenous MHC class I-related chain molecules A and B from different human tumor entities: Heterogeneous involvement of the “a disintegrin and metalloproteases” 10 and 17

(2013) Guranda Chitadze et al.   INTERNATIONAL JOURNAL OF CANCER

The bispecific immunoligand ULBP2-aCEA redirects natural killer cells to tumor cells and reveals potent anti-tumor activity against colon carcinoma

(2013) Achim Rothe et al.   INTERNATIONAL JOURNAL OF CANCER

New prospects on the NKG2D/NKG2DL system for oncology

(2013) Evelyn Ullrich et al.   OncoImmunology

RAE-1 ligands for the NKG2D receptor are regulated by E2F transcription factors, which control cell cycle entry

(2012) Heiyoun Jung et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Complex regulation of human NKG2D-DAP10 cell surface expression: opposing roles of the  c cytokines and TGF- 1

(2011) Y. P. Park et al.   BLOOD

Cancer Immunotherapy Using a Bispecific NK Receptor Fusion Protein that Engages both T Cells and Tumor Cells

(2011) T. Zhang et al.   CANCER RESEARCH

Tumor Suppressive MicroRNAs miR-34a/c Control Cancer Cell Expression of ULBP2, a Stress-Induced Ligand of the Natural Killer Cell Receptor NKG2D

(2011) A. Heinemann et al.   CANCER RESEARCH

Treatment of multiple myeloma with adoptively transferred chimeric NKG2D receptor-expressing T cells

(2011) A Barber et al.   GENE THERAPY

TGF-  downregulates the activating receptor NKG2D on NK cells and CD8+ T cells in glioma patients

(2011) C. A. Crane et al.   NEURO-ONCOLOGY

Inhibition of NKG2D expression in NK cells by cytokines secreted in response to human cytomegalovirus infection

(2010) A. Muntasell et al.   BLOOD

Natural Killer Cell Cytotoxicity Is Suppressed by Exposure to the Human NKG2D Ligand MICA*008 That Is Shed by Tumor Cells in Exosomes

(2010) O. Ashiru et al.   CANCER RESEARCH

Single nucleotide polymorphism analysis of the NKG2D ligand cluster on the long arm of chromosome 6: Extensive polymorphisms and evidence of diversity between human populations

(2010) Ayman Antoun et al.   HUMAN IMMUNOLOGY

Comparative genomic analysis of mammalian NKG2D ligand family genes provides insights into their origin and evolution

(2010) Mizuho Kondo et al.   IMMUNOGENETICS

Differential Mechanisms of Shedding of the Glycosylphosphatidylinositol (GPI)-anchored NKG2D Ligands

(2010) Lola Fernández-Messina et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Cutting Edge: The Membrane Type Matrix Metalloproteinase MMP14 Mediates Constitutive Shedding of MHC Class I Chain-Related Molecule A Independent of A Disintegrin and Metalloproteinases

(2010) G. Liu et al.   JOURNAL OF IMMUNOLOGY

Differential NKG2D binding to highly related human NKG2D ligands ULBP2 and RAET1G is determined by a single amino acid in the α2 domain

(2009) Mareike Wittenbrink et al.   EUROPEAN JOURNAL OF IMMUNOLOGY

ULBP6/RAET1L is an additional human NKG2D ligand

(2009) Robert A. Eagle et al.   EUROPEAN JOURNAL OF IMMUNOLOGY

Identification of natural killer cell receptor clusters in the platypus genome reveals an expansion of C-type lectin genes

(2009) Emily S. W. Wong et al.   IMMUNOGENETICS

Posttranslational regulation of the NKG2D ligand Mult1 in response to cell stress

(2009) Timothy J. Nice et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Normally occurring NKG2D+CD4+T cells are immunosuppressive and inversely correlated with disease activity in juvenile-onset lupus

(2009) Zhenpeng Dai et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Heat Shock Protein-90 Inhibitors Increase MHC Class I-Related Chain A and B Ligand Expression on Multiple Myeloma Cells and Their Ability to Trigger NK Cell Degranulation

(2009) C. Fionda et al.   JOURNAL OF IMMUNOLOGY

Proteasome Regulation of ULBP1 Transcription

(2009) James E. Butler et al.   JOURNAL OF IMMUNOLOGY

Effective in vivo induction of NKG2D ligands in acute myeloid leukaemias by all-trans-retinoic acid or sodium valproate

(2009) A Poggi et al.   LEUKEMIA

The role of the activating receptor NKG2D in autoimmunity

(2009) Tom L. Van Belle et al.   MOLECULAR IMMUNOLOGY

Induction of MHC class I-related chain B (MICB) by 5-aza-2′-deoxycytidine

(2008) Kai-Fu Tang et al.   BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS

ATM-ATR-dependent up-regulation of DNAM-1 and NKG2D ligands on multiple myeloma cells by therapeutic agents results in enhanced NK-cell susceptibility and is associated with a senescent phenotype

(2008) A. Soriani et al.   BLOOD

Selective Induction of Expression of a Ligand for the NKG2D Receptor by Proteasome Inhibitors

(2008) M. Vales-Gomez et al.   CANCER RESEARCH

Tumor-Associated MICA Is Shed by ADAM Proteases

(2008) I. Waldhauer et al.   CANCER RESEARCH

Soluble NKG2D ligands: prevalence, release, and functional impact

(2008) Helmut Rainer Salih   Frontiers in Bioscience-Landmark

Interleukin-12 improves cytotoxicity of natural killer cells via upregulated expression of NKG2D

(2008) Cai Zhang et al.   HUMAN IMMUNOLOGY

NKG2D-Deficient Mice Are Defective in Tumor Surveillance in Models of Spontaneous Malignancy

(2008) Nadia Guerra et al.   IMMUNITY

Human microRNAs regulate stress-induced immune responses mediated by the receptor NKG2D

(2008) Noam Stern-Ginossar et al.   NATURE IMMUNOLOGY

NK cells and cancer immunosurveillance

(2008) I Waldhauer et al.   ONCOGENE